1
|
Choi UY, Kim KH, Cho HK, Kim DH, Ma SH, Choi YY, Kim CS, Capeding MR, Kobashi IAR, Kim H, Ryu JH, Lee SJ, Park HK, Kim JH. Immunogenicity and Safety of a Newly Developed Live Attenuated Varicella Vaccine in Healthy Children: A Multi-National, Randomized, Double-Blinded, Active-Controlled, Phase 3 Study. Vaccines (Basel) 2023; 11:1416. [PMID: 37766093 PMCID: PMC10537027 DOI: 10.3390/vaccines11091416] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 08/07/2023] [Accepted: 08/21/2023] [Indexed: 09/29/2023] Open
Abstract
Korean manufacturers have developed a new varicella vaccine, NBP608. This phase 3, randomized, double-blind, multicenter study aimed to compare the immunogenicity and safety of NBP608 in healthy children to those of VarivaxTM (control). Children aged 12 months to 12 years were randomized in a ratio of 1:1 to receive either NBP608 or the control vaccine. Serum samples were obtained before vaccination and within six to eight weeks after vaccination. In total, 499 participants (NBP608, n = 251; control, n = 248) were enrolled. The seroconversion rate (SCR) measured using a FAMA assay was 99.53% in the NBP608 group, and the lower limit of the 95% confidence interval (95% LCL) for the SCR difference (NBP608 minus the control) was 0.52%. This 95% LCL for the difference was higher than the specified non-inferiority margin of -15%. In an assessment using gpELISA, the SCR was 99.53% in the NBP608 group, and the 95% LCL for the SCR difference was 6.5%, which was higher than the specified non-inferiority margin of -15%. There were no significant differences between the NBP608 and control group with respect to the proportions of participants who demonstrated local and systemic solicited AEs. This study indicated that NBP608 had a clinically acceptable safety profile and was not immunologically inferior to VarivaxTM.
Collapse
Affiliation(s)
- Ui Yoon Choi
- Department of Pediatrics, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of Korea;
| | - Ki Hwan Kim
- Department of Pediatrics, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 21431, Republic of Korea;
| | - Hye-Kyung Cho
- Department of Pediatrics, Gachon University College of Medicine, Incheon 21936, Republic of Korea;
| | - Dong Ho Kim
- Department of Pediatrics, Korea Cancer Center Hospital, Seoul 01812, Republic of Korea;
| | - Sang Hyuk Ma
- Department of Pediatrics, Changwon Fatima Hospital, Changwon 51394, Republic of Korea;
| | - Young Youn Choi
- Department of Pediatrics, Chonnam National University Medical School, Gwangju 61469, Republic of Korea;
| | - Chun Soo Kim
- Department of Pediatrics, Keimyung University School of Medicine, Daegu 42601, Republic of Korea;
| | - Maria Rosario Capeding
- Department of Microbiology, Research Institute for Tropical Medicine, Manila 1781, Philippines;
| | | | - Hun Kim
- SK Bioscience, Seongnam 13494, Republic of Korea; (H.K.); (J.H.R.); (S.J.L.); (H.K.P.)
| | - Ji Hwa Ryu
- SK Bioscience, Seongnam 13494, Republic of Korea; (H.K.); (J.H.R.); (S.J.L.); (H.K.P.)
| | - Su Jeen Lee
- SK Bioscience, Seongnam 13494, Republic of Korea; (H.K.); (J.H.R.); (S.J.L.); (H.K.P.)
| | - Ho Keun Park
- SK Bioscience, Seongnam 13494, Republic of Korea; (H.K.); (J.H.R.); (S.J.L.); (H.K.P.)
| | - Jong-Hyun Kim
- Department of Pediatrics, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon 16247, Republic of Korea
| |
Collapse
|
2
|
Mo ZJ, Huang SJ, Qiu LX, Li CG, Yu XJ, Li MQ, Chen Z, Zhong GH, Pan DQ, Huang LR, Lv BJ, Cui XL, Song QQ, Jia JZ, Han JL, Wang W, Zhu H, Cheng T, Su YY, Li YM, Ye XZ, Wu T, Zhang J, Xia NS. Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial. THE LANCET REGIONAL HEALTH - WESTERN PACIFIC 2023. [DOI: 10.1016/j.lanwpc.2023.100707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
3
|
Choi B, Kwon S. Seroprevalence comparison of different varicella vaccines among Turkish children. Hum Vaccin Immunother 2022; 18:2067443. [PMID: 35446747 PMCID: PMC9302503 DOI: 10.1080/21645515.2022.2067443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Affiliation(s)
- BongKyoo Choi
- Department of Research and Development, GC Pharma, Yongin, South Korea.,Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
| | - ShiNae Kwon
- Department of Research and Development, GC Pharma, Yongin, South Korea
| |
Collapse
|
4
|
Choi B, Cho H, Shin Y, Lee EK. Letter to the Editor: Effectiveness of the Varicella Vaccine Among Korean Children: Suggestions for Future Research. J Korean Med Sci 2022; 37:e17. [PMID: 34981684 PMCID: PMC8723895 DOI: 10.3346/jkms.2022.37.e17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 12/22/2021] [Indexed: 11/26/2022] Open
Affiliation(s)
- BongKyoo Choi
- Department of Research and Development, GC Pharma, Yongin, Korea
- Department of Medicine, University of California, Irvine, CA, USA
- Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.
| | - Hyunjeong Cho
- Department of Research and Development, GC Pharma, Yongin, Korea
| | - Younchul Shin
- Department of Research and Development, GC Pharma, Yongin, Korea
| | - Eun-Kyoung Lee
- Department of Research and Development, GC Pharma, Yongin, Korea
| |
Collapse
|